Experimental cell therapy targets hard-to-treat blood disorder
NCT ID NCT07091370
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This early-stage trial tests a new cell therapy (Inaticabtagene Autoleucel) for people with autoimmune hemolytic anemia that hasn't improved after at least three other treatments. The study will enroll 12 adults aged 18-75 to check if the treatment is safe and tolerable. The goal is to find a safe dose and see if it can control the disease by improving red blood cell counts and reducing symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.